Neoadjuvant Intravenous Oncolytic Vaccinia Virus Therapy Promotes Anticancer Immunity in Patients
Open Access
- 19 April 2022
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Immunology Research
- Vol. 10 (6), 745-756
- https://doi.org/10.1158/2326-6066.cir-21-0171
Abstract
Improving the chances of curing cancer patients who have had surgery to remove metastatic sites of disease is a priority area for cancer research. Pexa-Vec (Pexastimogene Devacirepvec; JX-594, TG6006) is a principally immunotherapeutic oncolytic virus that has reached late-phase clinical trials. We report the results of a single-center, non-randomized biological endpoint study (trial registration: EudraCT number 2012-000704-15), which builds on the success of the pre-surgical intravenous (i.v.) delivery of oncolytic viruses to tumors. Nine patients with either colorectal cancer liver metastases (CRLM) or metastatic melanoma were treated with a single i.v. infusion of Pexa-Vec ahead of planned surgical resection of the metastases. Grade 3 and 4 Pexa-Vec-associated side-effects were lymphopaenia and neutropaenia. Pexa-Vec was peripherally carried in plasma and was not associated with peripheral blood mononuclear cells (PBMCs). Upon surgical resection, Pexa-Vec was found in the majority of analyzed tumors. Pexa-Vec therapy associated with interferon-α secretion, chemokine induction, and resulted in transient innate and long-lived adaptive anti-cancer immunity. In the two patients with significant and complete tumor necrosis, a reduction in the peripheral T-cell receptor diversity was observed at the time of surgery. These results support the development of pre-surgical oncolytic vaccinia virus-based therapies to stimulate anti-cancer immunity and increase the chances to cure patients with cancer.Keywords
Other Versions
This publication has 50 references indexed in Scilit:
- Tumor-infiltrating lymphocytes in colorectal tumors display a diversity of T cell receptor sequences that differ from the T cells in adjacent mucosal tissueCancer Immunology, Immunotherapy, 2013
- Cytotoxic and immune‐mediated killing of human colorectal cancer by reovirus‐loaded blood and liver mononuclear cellsInternational Journal of Cancer, 2012
- A Mechanistic Proof-of-concept Clinical Trial With JX-594, a Targeted Multi-mechanistic Oncolytic Poxvirus, in Patients With Metastatic MelanomaMolecular Therapy, 2011
- FLASH: fast length adjustment of short reads to improve genome assembliesBioinformatics, 2011
- Internalization of Oncolytic Reovirus by Human Dendritic Cell Carriers Protects the Virus from NeutralizationClinical Cancer Research, 2011
- Measuring dementia carers' unmet need for services - an exploratory mixed method studyBMC Health Services Research, 2010
- Chemokine Expression in Melanoma Metastases Associated with CD8+ T-Cell RecruitmentCancer Research, 2009
- Monocyte derived dendritic cells generated by IFN-α acquire mature dendritic and natural killer cell properties as shown by gene expression analysisJournal of Translational Medicine, 2007
- Upregulation of PD-1 Expression on Circulating and Intrahepatic Hepatitis C Virus-Specific CD8+T Cells Associated with Reversible Immune DysfunctionJournal of Virology, 2007
- Protective Immunity against Secondary Poxvirus Infection Is Dependent on Antibody but Not on CD4 or CD8 T-Cell FunctionJournal of Virology, 2006